It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the Substantia nigra pars compacta (SNpc). Apoptosis is thought to play a critical role in the progression of PD, and thus understanding the effects of antiapoptotic strategies is crucial for developing potential therapies. In this study, we developed a unique genetic model to selectively delete Casp3, the gene encoding the apoptotic protein caspase-3, in dopaminergic neurons (TH-C3KO) and investigated its effects in response to a subacute regime of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration, which is known to trigger apoptotic loss of SNpc dopaminergic neurons. We found that Casp3 deletion did not protect the dopaminergic system in the long term. Instead, we observed a switch in the cell death pathway from apoptosis in wild-type mice to necrosis in TH-C3KO mice. Notably, we did not find any evidence of necroptosis in our model or in in vitro experiments using primary dopaminergic cultures exposed to 1-methyl-4-phenylpyridinium in the presence of pan-caspase/caspase-8 inhibitors. Furthermore, we detected an exacerbated microglial response in the ventral mesencephalon of TH-C3KO mice in response to MPTP, which mimicked the microglia neurodegenerative phenotype (MGnD). Under these conditions, it was evident the presence of numerous microglial phagocytic cups wrapping around apparently viable dopaminergic cell bodies that were inherently associated with galectin-3 expression. We provide evidence that microglia exhibit phagocytic activity towards both dead and stressed viable dopaminergic neurons through a galectin-3-dependent mechanism. Overall, our findings suggest that inhibiting apoptosis is not a beneficial strategy for treating PD. Instead, targeting galectin-3 and modulating microglial response may be more promising approaches for slowing PD progression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Lund University, Experimental Neuroinflammation Laboratory, Department of Experimental Medical Science, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
2 IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Instituto de Biomedicina de Sevilla, Seville, Spain (GRID:grid.414816.e) (ISNI:0000 0004 1773 7922); Universidad de Sevilla, Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Seville, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229)
3 Universidad de Sevilla, Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Seville, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229); Universidad Loyola Andalucía, Faculty of Health Sciences, Seville, Spain (GRID:grid.449008.1) (ISNI:0000 0004 1795 4150)
4 IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Instituto de Biomedicina de Sevilla, Seville, Spain (GRID:grid.414816.e) (ISNI:0000 0004 1773 7922); University of Seville, Department of Medical Biochemistry, Molecular Biology and Immunology, School of Medicine, Seville, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229)
5 Karolinska Institutet, Institute of Environmental Medicine, Toxicology Unit, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Shui On Centre, Center for Neuromusculoskeletal Restorative Medicine, Wan Chai, Hong Kong (GRID:grid.4714.6)